FDA Warns Amgen Over Misleading Cancer Drug Promotional Video
The FDA said an Amgen video promoting its colorectal cancer drug highlighted benefits but did not adequately disclose serious safety risks and patient limitations.
The US FDA on Tuesday warned Amgen NASDAQ:AMGN that a promotional video for its colorectal cancer drug was misleading because it highlighted the benefits while failing to adequately disclose serious safety risks and patient limitations.Here are some details